ACE2 and COVID-19: Researchers have suggested that subjects with hypertension may experience a decreased ACE2 expression, which, when bound by SARS-CoV-2, attenuates residual ACE2, leading to elevated angiotensin II levels, driving the development of COVID-19 and its severity [35].